By Market & Region

SHERIDAN, WYOMING – August 26, 2025 – GS1 Germany and Meta are set to co-host the Retail Summit 2025 on November 5 in Cologne, bringing together leading retailers, technology providers, and brand executives to explore how artificial intelligence, retail media, and immersive experiences are reshaping commerce across Europe. Under the theme “Where Technology Meets Experience,” the event aims to highlight best practices from both established brands and Silicon Valley innovators.

A Platform for Retail AI and Emerging Technologies

SHERIDAN, WYOMING – August 26, 2025 – Zukunft Personal Europe (ZP Europe) is set to mark its 25th anniversary with a forward-looking edition in Cologne from September 9–11, 2025. Positioned under the theme “Time for New Beginnings”, the event will move beyond retrospectives to highlight transformation strategies, cutting-edge HR technology, and organizational models for a rapidly evolving workplace.

From HR Fair to European Transformation Hub

Once launched as a specialized HR trade fair, Zukunft Personal has evolved into Europe’s leading platform for people and organizational performance. In 2025, the anniversary event aims to showcase how businesses can address interconnected challenges in leadership, digitalization, workplace culture, and resilience. Organizers emphasize that the focus is no longer just human resources, but broader structural change shaping enterprises across industries.

SHERIDAN, WYOMING – August 12, 2025 – Eli Lilly’s Phase III results for its next-generation oral GLP-1 therapy, orforglipron, have energized the already competitive obesity drug market, sparking renewed focus on oral weight-loss candidates poised to challenge the injectable-dominated landscape. While Lilly’s data confirmed significant efficacy, industry analysts see room for competitors to gain ground with differentiated mechanisms, dosing advantages, and manufacturing scalability.

The ATTAIN-1 study showed orforglipron achieved an average 12.4% weight reduction over 72 weeks, compared with 0.9% for placebo, with nearly 60% of high-dose patients losing at least 10% of body weight. However, analysts at Truist Securities and William Blair noted the therapy’s performance fell short of expectations set by leading injectable GLP-1 agonists—creating an opening for rivals.

Market Shift Toward Oral Obesity Therapies

SHERIDAN, WYOMING – August 12, 2025 – A wave of safety concerns surrounding adeno-associated virus (AAV) gene therapy has hit the biotechnology sector following multiple patient deaths linked to Sarepta Therapeutics’ platform. While some stakeholders push for urgent refinements to the decades-old technology, others are accelerating work on alternative delivery systems that could reshape the future of genetic medicine.

SHERIDAN, WYOMING – August 12, 2025 – The Department of Health and Human Services (HHS) is facing fresh turbulence after the abrupt dismissal of Gray Delany, the lead implementor of the Make America Healthy Again (MAHA) initiative. The move comes just days after Health Secretary Robert F. Kennedy Jr. terminated 22 mRNA vaccine contracts worth a combined $500 million, triggering intense debate across the biomedical and public health sectors.

SHERIDAN, WYOMING – August 12, 2025 – The U.S. Food and Drug Administration (FDA) has significantly tightened prescribing criteria for bluebird bio’s Skysona, an autologous hematopoietic stem cell-based gene therapy for cerebral adrenoleukodystrophy (CALD). The treatment is now limited to patients with no other therapeutic options or available stem cell donors, following post-marketing findings of a substantially higher incidence of hematologic malignancies than previously reported.

SHERIDAN, WYOMING – August 11, 2025 – The U.S. pharmaceutical sector faces a pivotal moment as recent federal funding cuts to mRNA vaccine programs threaten to slow one of oncology’s most promising frontiers: dendritic cell–based mRNA cancer immunotherapies. With the Department of Health and Human Services ending approximately $500 million in BARDA contracts, industry stakeholders are being called upon to bridge the gap and accelerate clinical translation.

Why mRNA Technology Is Critical for Cancer Immunotherapy

SHERIDAN, WYOMING – August 11, 2025 – Boehringer Ingelheim has secured FDA accelerated approval for its kinase inhibitor Hernexeos (zongertinib), marking the German pharmaceutical company’s first entry into the oncology market in its 140-year history. The approval positions Hernexeos as a new targeted therapy for adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD)–activating mutations.

Targeted Innovation in HER2-Mutant NSCLC
Hernexeos is designed as an oral, selective, and irreversible HER2 inhibitor that disrupts cell growth and division driven by HER2 signaling. By directly addressing this oncogenic pathway, the drug aims to provide a new treatment option for a patient subset that historically faces poor prognoses and limited targeted therapy choices.

SHERIDAN, WYOMING – August 10, 2025 – Midea Group will make a significant statement at this year’s IFA trade fair, occupying an expansive 2,600-square-meter exhibition space in Hall 5.1. The showcase will feature a diverse portfolio of home appliance and air conditioning solutions, with first-time participation from Küppersbusch Hausgeräte GmbH and its premium brands Küppersbusch and Teka, alongside U.S.-based vacuum cleaner specialist Eureka.

A Unified Platform for Global Brand Visibility

Under the overarching theme “Humanizing Technology,” Midea Group aims to highlight product innovations designed around user experience, energy efficiency, and lifestyle integration. For Küppersbusch and Teka, the event marks a strategic entry onto the IFA stage, allowing these European brands to strengthen their market positioning through direct engagement with international distributors, retailers, and technology partners.

SHERIDAN, WYOMING – August 10, 2025 – The GSMA is preparing to host one of the most significant technology gatherings of the decade as MWC Barcelona returns March 2–5, 2026, celebrating 20 years of convening global connectivity leaders. The milestone event aims to blend two decades of innovation with a forward-looking agenda focused on AI, 5G, enterprise technology, and policy shaping for the next generation of connected solutions.

Two Decades of Industry Collaboration and Impact

Since its inception, MWC Barcelona has served as a strategic platform where network operators, device manufacturers, policymakers, and technology investors converge. The event’s legacy is rooted in driving advancements in global communications, from the earliest mobile broadband rollouts to the current surge in edge computing, private networks, and IoT integration.

Elevating the Global Stage in 2026

SHERIDAN, WYOMING – August 10, 2025 – Eli Lilly is navigating a three-pronged challenge on drug pricing, from regulatory proposals to competitive market dynamics, even as it advances its next-generation oral weight loss candidate, orforglipron. On its second quarter earnings call, the company’s leadership underscored that pricing strategy will remain central to sustaining market share and delivering shareholder value.

Balancing Innovation and Pricing in Obesity Therapeutics

Lilly’s much-anticipated oral GLP-1 receptor agonist, orforglipron, is positioned to compete directly with Novo Nordisk’s blockbuster obesity portfolio. With the oral format offering improved patient convenience over injectable therapies, analysts expect robust uptake potential. However, the commercial rollout will hinge on a price point that supports payer coverage while defending against Most Favored Nation (MFN) pricing pressures at the federal level.

SHERIDAN, WYOMING – August 10, 2025 – Globus Medical, Inc. (NYSE: GMED) reported strong second-quarter 2025 results, achieving record non-GAAP earnings per share and double-digit revenue growth, driven by its U.S. Spine business and strategic integration of Nevro. The performance underscores the company’s operational discipline and its continued push to expand robotic-assisted surgery adoption.

Double-Digit Revenue Growth Across Core Segments

Worldwide net sales reached $745.3 million, an 18.4% year-over-year increase, or 17.6% on a constant currency basis. U.S. net sales rose 20.3%, while international revenue grew 11% as reported. The company’s Musculoskeletal Solutions segment generated $710.2 million, with Enabling Technologies contributing $35.2 million after a modest rebound in demand.

Operational Leverage and Profitability Milestones

SHERIDAN, WYOMING – August 10, 2025 – Gilead Sciences is signaling strong confidence in its HIV prevention portfolio, including the twice-yearly injectable PrEP therapy Yeztugo, despite growing uncertainty over the future of the U.S. Preventive Services Task Force (USPSTF). The federally recognized panel’s recommendations currently mandate insurance coverage for preventive services, but a postponed meeting has fueled speculation that Health Secretary RFK Jr. could overhaul or dismantle the group.

Regulatory Shifts Could Reshape PrEP Access

The USPSTF plays a critical role in defining access to preventive medicines by issuing recommendations that directly influence payer coverage. For HIV prevention, its endorsement has helped accelerate adoption of both oral and long-acting injectable PrEP solutions. A structural change to the task force could:

SHERIDAN, WYOMING – August 10, 2025 – In a rapid reversal, Dr. Vinay Prasad has resumed leadership of the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) less than two weeks after stepping down. The reinstatement, confirmed by the Department of Health and Human Services (HHS), ends speculation over the agency’s direction during a critical period for advanced biologics oversight.

FDA Leadership Transition Reverses Course

Prasad’s reinstatement follows his abrupt July 29 resignation, which had raised questions within regulatory, biotech, and patient advocacy circles. HHS spokesperson Andrew Nixon confirmed to STAT News that “At the FDA’s request, Dr. Vinay Prasad is resuming leadership of the Center for Biologics Evaluation and Research,” signaling a renewed alignment between CBER and the agency’s strategic objectives.

SHERIDAN, WYOMING – August 8, 2025 – Sailor Foods Co., Ltd., a long-established Chinese heritage food producer, has marked its 30th anniversary with a sweeping transformation plan that blends brand modernization, product innovation, and multi-channel market expansion. The company’s “Riding the Waves – Thirty Years and Leaping Ahead” customer appreciation event in Putian brought together nearly 1,000 industry partners, underscoring its ambitions to compete in both domestic and international markets over the next decade.

Brand Modernization to Align with New Consumer Era

SHERIDAN, WYOMING – August 9, 2025 – The global organic spirulina market is entering a period of unprecedented growth, with revenues projected to rise from $140 million in 2025 to $515 million by 2035, according to industry forecasts. This expansion, at a compound annual growth rate (CAGR) of 13.5%, reflects a broader shift toward clean-label, certified-organic products in both nutraceutical and functional food sectors.

SHERIDAN, WYOMING – August 9, 2025 – The cell and gene therapy (CGT) sector stands at a pivotal moment. Once buoyed by multibillion-dollar valuations, companies like Sarepta Therapeutics and bluebird bio have faced sharp declines, underscoring the sector’s commercial growing pains. Industry leaders now agree: sustainable success will depend on advancing manufacturing, aligning global regulations, and better communicating value to payers.

Next-Generation Manufacturing as a Growth Engine

Panelists at the recent BIO Convention in Boston pointed to decentralized, modular manufacturing as a critical enabler for CGT expansion. The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has taken the lead with formal guidelines for point-of-care production, a move welcomed by innovators like Ori Biotech CEO Jason Foster. In the U.S., the FDA has yet to implement a comparable framework.

SHERIDAN, WYOMING – August 8, 2025 – Major pharmaceutical companies are doubling down on venture funds and incubator programs to identify cutting-edge science, foster strategic partnerships, and position themselves in emerging therapeutic and geographic markets. While mergers and acquisitions remain a dominant growth driver, these initiatives provide a long-term “farm system” for high-value pipeline assets.

From Discovery Hubs to Strategic Pipelines
Eli Lilly’s Lilly Gateway Labs and Boehringer Ingelheim’s Venture Fund illustrate how Big Pharma is building innovation capacity beyond their core research programs. These initiatives target startups with disruptive science in neuroscience, oncology, immunology, and cardiometabolic health—while also venturing into high-risk areas such as neurodegenerative diseases and healthspan research.

SHERIDAN, WYOMING – August 8, 2025 – A wave of high-value licensing deals between multinational pharmaceutical companies and Chinese biotechs is reshaping the global drug development landscape. While the headlines highlight billion-dollar transactions, the reality on the ground is a complex mix of opportunity and survival for China’s crowded biotech sector.

Licensing as a Strategic Lifeline
Out-licensing overseas rights has become a critical strategy for Chinese biotechs facing tightened capital flows and rising operational pressures. For many, partnering with multinational corporations is not simply a growth choice — it’s a means to stay in business. Executives across China’s leading hubs, from Shanghai Zhangjiang Pharma Valley to Suzhou’s BioBAY, report that companies have been cutting staff, selling assets, or closing entirely since 2022.

SHERIDAN, WYOMING – August 8, 2025 – In a move aimed at reducing the nation’s dependence on overseas pharmaceutical production, the U.S. Food and Drug Administration (FDA) has launched PreCheck, a two-phase program designed to speed regulatory review and strengthen domestic drug manufacturing capacity.

A New Framework for Facility Readiness
PreCheck’s first stage, the Facility Readiness Phase, gives manufacturers more structured and frequent communication with the FDA at pivotal stages such as site design, construction, and pre-production. The process also incorporates Drug Master Files — detailed, facility-specific records that map layouts, workflows, and operations — to support earlier and more accurate regulatory evaluation.